A question unanswered is: how many of the patients on placebo felt they were on placebo and added new approved drugs to prednisone?
How to handle these patients' data during analysis?
Both cabo and foretinib are working on the same kinds of pathways. Wondering what will they perform if they combined at half of normal dosages.
One question for those familiar with trial. How many percent of patients on placebo can feel they are only on prednisone and add other recent-approved drugs? How to handle this part of patients in analysis?
When being asked if they have comet-1 data at hand, they answer: "we have not reached the 60% events yet, so we cannot unblind and do analysis.".
A lot of people will be puzzled watching our share price double with this piece of no news.
This is most important. If this group of sickest patients have median OS less than 7 months and they don't move to other approved drugs, and if we didn't reach 60% events, we will have a good readout.
We've already passed the longest estimate of 10 months. Considering the months before september2013, I believed somebody already knew the answer, even if it's not cleaned-up to the level for NDA. The less sick group in other trials, median OS is about 9 mos vs. 7 mos, and we wait for 60% events.
It's very weird that they updated RCC and HCC more often than COMET-2. The latest real change they made on clinicaltrials was 4/18/2014. 5/22 and 6/13 had nothing there.
What MITI did was a double-ended antibody, one linked to a cancer cell marker, another to recruit T-cell. This one from UPenn is to engineer T-cell progenitor and re-inject into human body.
I ain't no lucky person. MEDX, MITI, all these blockbusters for yard sale at a few cents...
Remember last time when human genome project revealed the whole sequence of human gene?
Now this little pig whipworm's genome has been presented by a international team of 11 institutions from 6 countries. Guess what's the purpose of this huge study?
tick tock tick......
You got it! Human autoimmune diseases!
Anybody said it's voodoo medicine? Guess the scientific society and the big money invested in the basic science didn't agree.
Just search pig whipworm genome.
As a human and a shareholder, I agree EXEL should donate cabo to her family. In a long time, cabo will not be approved for this cancer. And donating cabo will make exel's image brighter and more people will know it. It's much better than spending money on GS conference. Facebook is donating free advertisement for us, will we turn it down?
He just updated on clinicaltrials yesterday and anticipated to finish by this month. It's obvious he is reading the data. The question is whether he will update on the ICare4Autism conf or publish on magazine first.
every one of us is in the dark since the company didn't give us enough info. But my guess is it didn't take long to come up with a "continue" conclusion comparing to the preset high bar. Probably only a computer program told us that, not detailed analysis of individual info by human.
For the interim analysis, I don't think CRO need 2 weeks to tell us to proceed. It's not even a futile analysis. Just run a few numbers on HR and p. Not good enough to stop, no thorough analysis needed.
About the 60% events, I don't think they have to PR it. I can't recall any companies PR that: "we are doing final analyses of the final data, please wait...".
We have the sickest patients, 6 months after full enrollment(means some patients are before sept 2013), got only 40% events. That showed some efficacy, but they didn't give us interim p. 8 months now, has not reached 60%, good sign.
Thanks a lot. That 7.9 is for MDV3100 survival. If a patient progressed on 3100 and immediately moved to prednisone, what's the expectation? My feeling is probably far less than 8 months.